{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-072011","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.791674+00:00","generated_at":"2026-06-27T00:00:34.646751+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Fulcrum Therapeutics eliminates VP Finance role; appoints Gregory Tourangeau as principal accounting officer","bullets":["Effective March 11, 2022, Peter Thomson terminated as principal accounting officer due to elimination of VP Finance & Accounting position.","Mr. Thomson remains employed in a transitional capacity through April 1, 2022.","Gregory Tourangeau, currently Controller, appointed as principal accounting officer effective March 11, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-072011","json":"https://secwatch.observer/filing/0001193125-22-072011.json","markdown":"https://secwatch.observer/filing/0001193125-22-072011.md","text":"https://secwatch.observer/filing/0001193125-22-072011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522072011/0001193125-22-072011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522072011/d306646d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:00:34.646751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6bec779f3d","claim":"Peter Thomson was terminated as Principal Accounting Officer at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On March 4, 2022, Fulcrum Therapeutics, Inc. (“Fulcrum”) notified Mr. Peter Thomson of the elimination of the Vice President, Finance & Accounting position and, as a consequence, the termination of his role as Fulcrum’s principal accounting officer, effective as of March 11, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522072011/0001193125-22-072011-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"983c216afe","claim":"Gregory Tourangeau was appointed as Principal Accounting Officer at Fulcrum Therapeutics, Inc..","evidence_excerpt":"Fulcrum appointed Mr. Gregory Tourangeau, Fulcrum’s Controller, as principal accounting officer effective March 11, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522072011/0001193125-22-072011-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}